Precision BioSciences (DTIL) vs MediWound (MDWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precision BioSciences (DTIL) has outperformed MediWound (MDWD) over the past year, gaining 12.8% versus a loss of 29.5%. Over five years, MDWD leads with a -48.0% price change compared with -97.8% for DTIL. Precision BioSciences is the larger company by market cap ($177.5 million vs $160.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DTIL | MDWD |
|---|---|---|
| Share price | $6.43 | $12.42 |
| Market cap | $177.48M | $160.35M |
| 1-day change | +2.88% | -3.35% |
| YTD return | +54.57% | -32.72% |
| 1-year return | +12.81% | -29.53% |
| 5-year return | -97.81% | -47.97% |
| EPS (TTM) | $-1.35 | $-2.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.62 | $20.03 |
| 52-week low | $3.53 | $12.42 |
| Distance from 52-week high | -33.16% | -37.99% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +357.23% | +146.94% |
| Average volume | 287.13K | 84.67K |
| Shares outstanding | 27.60M | 12.91M |
| Employees | 67 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed MDWD by 42.3 percentage points over the past year.
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Health Care · Medicinal Chemicals and Botanical Products · 121 employees
DTIL vs MDWD FAQ
Which is bigger, Precision BioSciences or MediWound?
Precision BioSciences (DTIL) is larger, with a market capitalization of $177.48M compared with $160.35M for MediWound (MDWD).
Which stock has performed better over the past year, DTIL or MDWD?
DTIL returned +12.81% over the past 12 months, compared with -29.53% for MDWD (price return, excluding dividends). Past performance does not predict future results.
Are Precision BioSciences and MediWound in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Precision BioSciences and Medicinal Chemicals and Botanical Products for MediWound.